Horizon, Roche top list for pharma reputation among rare disease patient groups, survey finds

As rare disease drug research increases among large pharma companies, so do their reputations with rare disease patient groups. The latest survey in PatientView’s annual research found that 57% of patient advocates say the pharma industry’s reputation is “good” or “excellent.” That’s up from 33% five…
Click here to view original post